menu
    • menu
    [{"orgOrder":0,"company":"CorMedix","sponsor":"New Jersey Economic Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Taurolidine","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Catheter Lock Solution","sponsorNew":"CorMedix \/ New Jersey Economic Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ New Jersey Economic Development Authority"},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Taurolidine","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Catheter Lock Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ Not Applicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ Not Applicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"SunTrust Robinson Humphrey","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Taurolidine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ SunTrust Robinson Humphrey","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ SunTrust Robinson Humphrey"},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ Not Applicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ Not Applicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ Not Applicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ Not Applicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ Not Applicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CorMedix \/ Not Applicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Taurolidine","moa":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"CorMedix","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"CorMedix \/ RBC Capital Markets","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/ RBC Capital Markets"},{"orgOrder":0,"company":"CorMedix","sponsor":"ARC Dialysis, LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ ARC Dialysis, LLC","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ ARC Dialysis, LLC"},{"orgOrder":0,"company":"CorMedix","sponsor":"CorMedix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CorMedix \/ CorMedix","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/ CorMedix"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"CorMedix \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by CorMedix

    Menu

    CorMedix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CorMedix Inc. Announces New Commercial Agreement

                            Details : Through the agreement, Cordemix will supply DefenCath (taurolidine and heparin) to dialysis clinics for CRBSI in adult patients with kidney failure receiving chronic hemodialysis.

                            Brand Name : Defencath

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 19, 2024

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider

                            Details : The agreement aims for the supply of DefenCath, a combination of taurolidine, a thiadiazinane antimicrobial and heparin, an anti-coagulant, indicated to reduce catheter-related bloodstream infections.

                            Brand Name : DefenCath

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 28, 2024

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : ARC Dialysis, LLC

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

                            Details : Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.

                            Brand Name : Defencath

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 08, 2024

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : ARC Dialysis, LLC

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : RBC Capital Markets

                            Deal Size : $40.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

                            Details : CorMedix intends to use the net proceeds for the commercialization of Taurolock Hep500 (taurolidine), approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device.

                            Brand Name : Taurolock Hep500

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 28, 2023

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : RBC Capital Markets

                            Deal Size : $40.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

                            Details : DefenCath is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous cathe...

                            Brand Name : Defencath

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 21, 2023

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath

                            Details : DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous ca...

                            Brand Name : Defencath

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 16, 2023

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath

                            Details : DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous ca...

                            Brand Name : Defencath

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 01, 2023

                            Lead Product(s) : Taurolidine,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CorMedix Inc. Announces Regulatory and Manufacturing Updates

                            Details : Defencath is available in Europe and other territories under the brand name Neutrolin. It is used for catheter-related bloodstream infections in patients with end-stage renal disease receiving hemodialysis through a central venous catheter.

                            Brand Name : Defencath

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 08, 2022

                            Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cormedix Inc. Announces Resubmission Of New Drug Application For DefenCath

                            Details : DefenCath is being developed as a catheter lock solution with an initial indication of use for the reduction of catheter-related bloodstream infections (CRBSIs) in patients with renal failure who are receiving chronic hemodialysis via a central venous ca...

                            Brand Name : Defencath

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 28, 2022

                            Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Defencath

                            Details : U.S. FDA has accepted for filing the Company’s submitted New Drug Application (NDA) for Defencath™, its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (...

                            Brand Name : Defencath

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 31, 2020

                            Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth